Recently, Huang Guo, a party member and deputy director of the State Drug Administration, led a team to Beijing to conduct in-depth research on the research and development of cell and gene therapy products. The purpose of this survey is to understand the latest progress in this field, and to discuss policy guidance and R & D quality, so as to promote the high-quality development of the industry in this field. It is understood that cell and gene therapy products have become the frontier and hot spot of global medicine development. Under the guidance of the policy of the State Drug Administration, more than 400 cell and gene therapy products in China are conducting drug clinical trials, including nearly 100 stem cell products. The indications of these products cover many kinds of diseases, such as tumor, respiratory system, nervous system, cardiovascular system, digestive system, rheumatic immunity and so on.

Deputy Director Huang Guo stressed at the forum that drug regulatory authorities will further strengthen policy guidance to provide stronger support for the research and development of cell and gene therapy products. At the same time, he also proposed to improve the quality of research and development, improve the standards of the evaluation system, strengthen communication services, ensure that cell and gene therapy products can benefit patients as soon as possible, and contribute to the development of the national pharmaceutical industry. This survey has received strong support and participation from relevant departments and directly affiliated units of the State Drug Administration, Beijing Drug Administration, Beijing Economic and technological Development Zone and other departments. All parties will cooperate closely to promote the research and development of cell and gene therapy products, so as to inject new vitality and impetus into the development of China's pharmaceutical industry.